Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [¹⁷⁷Lu]Lu-PSMA I&T during long-term follow-up.

ABSTRACT:

Background

Radioligand therapy (RLT) with ¹⁷⁷Lu-labeled prostate-specific membrane antigen (PSMA) ligands is associated with prolonged overall survival (OS) in patients with advanced, metastatic castration-resistant prostate cancer (mCRPC). A substantial number of patients, however, are prone to treatment failure. We aimed to determine clinical baseline characteristics to predict OS in patients receiving [¹⁷⁷Lu]Lu-PSMA I&T RLT in a long-term follow-up.

Materials and methods

Ninety-two mCRPC patients treated with [¹⁷⁷Lu]Lu-PSMA I&T with a follow-up of at least 18 months were retrospectively identified. Multivariable Cox regression analyses were performed for various baseline characteristics, including laboratory values, Gleason score, age, pri

SUBMITTER: Hartrampf PE 

PROVIDER: S-EPMC9525362 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature